Cyclophosphamide Therapy Recommendations

Infection Prophylaxis

The American College of Rheumatology recommends that all patients on cyclophosphamide require Pneumocystis jirovecii pneumonia (PCP) prophylaxis with trimethoprim-sulfamethoxazole, regardless of indication or dosing regimen 1, 2, 3
The preferred regimen for PCP prophylaxis is trimethoprim-sulfamethoxazole 800/160 mg on alternate days or 400/80 mg daily, as recommended by the European League Against Rheumatism 1, 2, 3
Patients receiving cyclophosphamide for cancer, ANCA-associated vasculitis, lupus nephritis, or other autoimmune conditions should receive PCP prophylaxis, according to the American College of Rheumatology 1, 4, 5
Alternative prophylaxis agents should be considered if trimethoprim-sulfamethoxazole is contraindicated, as suggested by the European League Against Rheumatism 6

The European League Against Rheumatism recommends that mesna (2-mercaptoethanesulfonate sodium) is mandatory for all IV pulse cyclophosphamide to prevent hemorrhagic cystitis, which occurs in 6% of patients without protection 3, 6
Mesna binds to acrolein (the toxic metabolite responsible for bladder toxicity) and reduces urinary tract complications, according to the American College of Rheumatology 6
All patients treated with cyclophosphamide require periodic urinalysis for the duration of follow-up to screen for bladder cancer, as recommended by the American Urological Association 1

Fertility preservation counseling is mandatory before initiating cyclophosphamide, especially in younger patients, according to the American Society for Reproductive Medicine 6
The American College of Rheumatology recommends limiting total cumulative cyclophosphamide dose to <25 g (maximum 36 g) to reduce secondary malignancy risk, and to 10 g for patients desiring fertility preservation 7

The European League Against Rheumatism recommends periodic bone density assessment in all patients with prolonged glucocorticoid treatment (which typically accompanies cyclophosphamide) 2

The American College of Rheumatology recommends completing age-appropriate vaccinations before initiating cyclophosphamide when possible, as the drug impairs humoral vaccine response 2
Cyclophosphamide therapy can lead to clinically relevant secondary hypogammaglobulinemia, according to the European League Against Rheumatism 2

The American College of Rheumatology recommends complete blood count monitoring to detect acute leukopenia or gradual decline in white blood cell counts, with dose adjustments or discontinuation as necessary 3, 6, 7

The European League Against Rheumatism recommends age-appropriate cancer screening, with enhanced surveillance for cyclophosphamide-treated patients, including specific screening for bladder cancer, myeloid leukemia, and skin cancer 2
Secondary malignancies represent a long-term risk that increases with cumulative cyclophosphamide exposure, according to the American College of Rheumatology 3, 6

Forced diuresis with intravenous fluids reduces the frequency and severity of bladder toxicity in patients receiving cyclophosphamide. 8
Regular urinary‑sediment monitoring during cyclophosphamide therapy helps detect erythrocytes and early urothelial toxicity. 8
A complete blood count should be obtained to identify anemia that may require transfusion support in hemorrhagic cystitis. 8

Analgesics are recommended for bladder spasm and dysuria, with avoidance of NSAIDs in thrombocytopenic patients. 8

Supportive care—including aggressive hydration and, when needed, continuous bladder irrigation—is the primary management strategy for BK‑virus–associated hemorrhagic cystitis. 9

Cidofovir shows antiviral activity against BK virus but carries a high risk of renal toxicity; therefore it is reserved for severe, refractory cases. 9
Current evidence is insufficient to support routine antiviral treatment of BK virus in hemorrhagic cystitis. 9
Cidofovir should not be administered empirically unless BK viruria is ≥10⁴ copies/mL, to avoid unnecessary nephrotoxicity. 9

Aggressive hydration and continuous bladder irrigation are recommended for radiation‑induced hemorrhagic cystitis, mirroring the supportive approach used for chemotherapy‑induced cases. 10
Management may need to be prolonged because mucosal injury persists throughout fractionated radiotherapy. 10
Hyperbaric oxygen therapy is considered for late‑stage radiation‑induced hemorrhagic cystitis. 10